Financial Performance
- Net Income: CAD -10.74M, a notable decrease year-over-year with a margin impacted by research and development (R&D) investments.
- Operating Income: CAD -13.29M, with an increase in operating expenses to CAD 12.09M, primarily driven by R&D efforts.
- Earnings Per Share (EPS): CAD -0.057 per share, reflecting the ongoing investments and strategic direction.
Cash Flow and Liquidity
- Cash at End of Period: CAD 22.51M, sufficient to cover operational needs for potential upcoming investments in clinical trials.
- Net Cash Used in Operating Activities: CAD -10.77M, indicative of significant operational expenditures prevalent in biotech startups.
Balance Sheet Strength
- Current Ratio: 6.89, indicating robust liquidity to meet short-term obligations.
- Total Assets: CAD 60.69M, indicating a strong asset base with a significant portion in cash and equivalents.
- Total Liabilities: CAD 4.37M, portraying minimal debt exposure, favorable for maintaining operational flexibility.